[go: up one dir, main page]

PE20080376A1 - Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina - Google Patents

Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina

Info

Publication number
PE20080376A1
PE20080376A1 PE2007000840A PE2007000840A PE20080376A1 PE 20080376 A1 PE20080376 A1 PE 20080376A1 PE 2007000840 A PE2007000840 A PE 2007000840A PE 2007000840 A PE2007000840 A PE 2007000840A PE 20080376 A1 PE20080376 A1 PE 20080376A1
Authority
PE
Peru
Prior art keywords
fluorophenylpyridine
sodium
thrombin receptor
receptor antagonist
immediate release
Prior art date
Application number
PE2007000840A
Other languages
English (en)
Inventor
Rajan Gupta
Suliman Chawdry
Srinivas S Duggirala
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20080376A1 publication Critical patent/PE20080376A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN COMPUESTO TRICICLICO DERIVADO DE FLUOROFENILPIRIDINA DE FORMULA (1) Y UN DESINTEGRANTE TAL COMO CROSCARMELOSA SODICA, ALMIDON, CROSPOVIDONA, ALMIDON GLICOLATO DE SODIO Y CELULOSA MICROCRISTALINA, DONDE LA PROPORCION DEL COMPUESTO (1) ES MENOR DEL 10% DEL PESO DE LA COMPOSICION. DICHA COMPOSICION TAMBIEN PUEDE COMPRENDER UN AGLUTINANTE TAL COMO POVIDONA, ALMIDON PREGELATINIZADO, GELATINA, ENTRE OTROS; UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO, ACIDO ESTEARICO Y TALCO; UN DILUYENTE TAL COMO MANITOL, SORBITOL, CELULOSA MICROCRISTALINA, ENTRE OTROS. EL COMPUESTO DE FORMULA (1) ES ANTAGONISTA DEL RECEPTOR DE TROMBINA
PE2007000840A 2006-06-30 2007-07-02 Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina PE20080376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81782106P 2006-06-30 2006-06-30

Publications (1)

Publication Number Publication Date
PE20080376A1 true PE20080376A1 (es) 2008-06-13

Family

ID=38895141

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000840A PE20080376A1 (es) 2006-06-30 2007-07-02 Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina

Country Status (18)

Country Link
US (2) US20080031943A1 (es)
EP (2) EP2034969B1 (es)
JP (2) JP5116764B2 (es)
KR (1) KR20090023670A (es)
CN (2) CN104922054A (es)
AR (1) AR061790A1 (es)
AU (1) AU2007269733B2 (es)
BR (1) BRPI0713935A2 (es)
CA (1) CA2656395C (es)
CL (1) CL2007001923A1 (es)
CO (1) CO6150126A2 (es)
ES (2) ES2616354T3 (es)
MX (1) MX2009000131A (es)
NO (1) NO20090467L (es)
PE (1) PE20080376A1 (es)
TW (1) TWI367112B (es)
WO (1) WO2008005353A2 (es)
ZA (1) ZA200900350B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
MX2009006873A (es) * 2006-12-22 2009-07-03 Schering Corp Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
US8624050B2 (en) * 2007-06-22 2014-01-07 General Electric Company Solution process for transparent conductive oxide coatings
CL2008003749A1 (es) 2007-12-17 2010-01-15 Janssen Pharmaceutica Nv Compuestos derivados de imidazol, oxazol, y tiazol pirimidina, moduladores de trpv1, proceso de preparacion, composicion farmaceutica y su uso en el tratamiento de enfermedades, trastornos o condicion de dolor, prurito, artritis, tos, asma, trastorno del oido interno y enfermedad inflamatoria intestinal, entre otras.
DK2438060T3 (da) 2009-06-04 2014-01-13 Merck Sharp & Dohme Aktiv metabolit af en trombin-receptor-antagonist
CA2764172A1 (en) * 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
CN102442965B (zh) * 2010-09-30 2013-12-11 天津药物研究院 用于治疗血栓性疾病的par-1拮抗剂及其制备方法和用途
WO2017134200A1 (en) 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
JP2021512869A (ja) * 2018-02-02 2021-05-20 ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） 経口製剤及びその使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61137813A (ja) * 1984-12-07 1986-06-25 Sawai Seiyaku Kk 持続性セフラジン製剤
JPS63162620A (ja) * 1986-12-25 1988-07-06 Teisan Seiyaku Kk 遅溶性顆粒及びそれを用いた持続性複合顆粒
GB9414045D0 (en) * 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
US20010003588A1 (en) * 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
JPH10130142A (ja) * 1996-10-31 1998-05-19 Zensei Yakuhin Kogyo Kk 放出持続型圧縮製剤
JPH10298062A (ja) * 1997-04-24 1998-11-10 Pfizer Pharmaceut Co Ltd 口腔内速溶型錠剤
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
WO1999026943A1 (en) * 1997-11-25 1999-06-03 Schering Corporation Thrombin receptor antagonists
US6630451B1 (en) 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
WO2001000656A2 (en) 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
MXPA02012447A (es) * 2000-06-15 2003-04-25 Schering Corp Antagonistas receptores de trombina.
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
JP2005500253A (ja) * 2001-02-23 2005-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物
ES2462995T3 (es) 2001-04-19 2014-05-27 Eisai R&D Management Co., Ltd. Derivados de 2-iminoisoindolinona como antagonistas del receptor de la trombina
AR036832A1 (es) 2001-10-18 2004-10-06 Schering Corp Compuestos derivados de himbacina, agonistas receptores de trombina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de medicamentos
PT1495018E (pt) * 2002-04-16 2008-02-19 Schering Corp Antagonistas tricíclicos de receptores de trombina
DE10317816A1 (de) * 2003-04-16 2004-11-04 Claas Selbstfahrende Erntemaschinen Gmbh Feldhäcksler mit positionierbarer Fahrerkabine
CZ300438B6 (cs) * 2003-11-25 2009-05-20 Pliva Hrvatska D.O.O. Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
JP2009521472A (ja) * 2005-12-22 2009-06-04 シェーリング コーポレイション 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
EP2037909A2 (en) * 2006-06-30 2009-03-25 Schering Corporation Solid dose formulations of a thrombin receptor antagonist
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
MX2009006873A (es) * 2006-12-22 2009-07-03 Schering Corp Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
EP2134344A1 (en) * 2007-03-23 2009-12-23 Schering Corporation Reduction of adverse events.after percutaneous intervention by use of a thrombin receptor antagonist

Also Published As

Publication number Publication date
AU2007269733B2 (en) 2013-02-21
CN104922054A (zh) 2015-09-23
EP2491922B1 (en) 2017-01-04
TW200810792A (en) 2008-03-01
EP2034969A2 (en) 2009-03-18
JP2012126752A (ja) 2012-07-05
BRPI0713935A2 (pt) 2012-12-04
CL2007001923A1 (es) 2008-02-08
TWI367112B (en) 2012-07-01
NO20090467L (no) 2009-03-19
WO2008005353A2 (en) 2008-01-10
JP5116764B2 (ja) 2013-01-09
AU2007269733A1 (en) 2008-01-10
CA2656395C (en) 2016-12-13
CN101511345A (zh) 2009-08-19
US20170224666A9 (en) 2017-08-10
ES2616354T3 (es) 2017-06-12
CA2656395A1 (en) 2008-01-10
MX2009000131A (es) 2009-01-26
KR20090023670A (ko) 2009-03-05
EP2034969B1 (en) 2017-01-11
CO6150126A2 (es) 2010-04-20
ES2616405T3 (es) 2017-06-13
AR061790A1 (es) 2008-09-24
ZA200900350B (en) 2010-01-27
US20080031943A1 (en) 2008-02-07
EP2491922A1 (en) 2012-08-29
US20160193196A1 (en) 2016-07-07
WO2008005353A3 (en) 2008-06-26
JP2009542678A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
PE20080376A1 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina
CO6150163A2 (es) Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina
HRP20090235A2 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub>
PE20090015A1 (es) Preparacion solida
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
ECSP077987A (es) Formulación de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberación modificada
MA30781B1 (fr) Inhibiteur de kinase
MA37405A1 (fr) Composés hétérocyclyle
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
CA2725933A1 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
RU2008135718A (ru) Композиции клопидогреля бисульфата
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
ATE418548T1 (de) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
PE20121131A1 (es) Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina
PE20070698A1 (es) Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
PE20071315A1 (es) Formulaciones de compuestos derivados de fenilo y procesos de preparacion para tabletas que contienen dichos compuestos
ECSP055762A (es) 4-amino-1-(piridilmetil)piperidina sustituida como antagonistas de receptores muscarinicos
ES2556235T3 (es) Arilsulfonamidas 2,5-disustituidas antagonistas de CCR3
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan

Legal Events

Date Code Title Description
FC Refusal